<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cobimetinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cobimetinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cobimetinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="105606" href="/d/html/105606.html" rel="external">see "Cobimetinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45691974"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cotellic</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872094"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cotellic</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45624165"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, MEK Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F45655180"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="032320cd-42d1-4ad3-866d-3a32ae0484f9">Histiocytic neoplasms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histiocytic neoplasms: Oral: </b>60 mg once daily on days 1 to 21 of each 28-day treatment cycle (as a single agent) until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b8b61a8-a96f-4706-a076-2ede2ffc94b3">Melanoma, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic (with BRAF V600E or V600K mutations):</b>
<b>Oral:</b> 60 mg once daily on days 1 to 21 of each 28-day treatment cycle (in combination with vemurafenib) until disease progression or unacceptable toxicity (Larkin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combination:</i>
<b>Oral:</b> 60 mg once daily on days 1 to 21 of each 28-day treatment cycle (in combination with atezolizumab and vemurafenib) until disease progression or unacceptable toxicity; prior to initiating atezolizumab, patients should receive a 28-day treatment cycle of cobimetinib and vemurafenib (Gutzmer 2020). Refer to protocol for further information.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>If a dose is missed or if vomiting occurs after a dose is taken, resume with the next scheduled dose (do not take an additional dose).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991362"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There is no dosage adjustment provided in the manufacturer’s labeling (has not been established).</p></div>
<div class="block doha drugH1Div" id="F50988546"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment: </i>Mild, moderate, or severe impairment (Child Pugh class A, B, or C): No initial dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">First occurrence of grade 4 lab abnormality (ALT, AST, or alkaline phosphatase &gt;20 times ULN or total bilirubin &gt;10 times ULN) or hepatotoxicity: Withhold cobimetinib for up to 4 weeks; if improves to grades 0 or 1, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved to grade 0 or 1 within 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Recurrent grade 4 lab abnormality or hepatotoxicity: Permanently discontinue cobimetinib.</p></div>
<div class="block dot drugH1Div" id="F45655184"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Recommended Cobimetinib Dose Reduction Levels for Toxicity</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initial (usual) dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">40 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">If unable to tolerate 20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cobimetinib.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<b>Note:</b> If using in combination, vemurafenib may also require dosage adjustment.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Cobimetinib</b>
<b> Dosage Modifications<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Target organ</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>LVEF = left ventricular ejection fraction.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cardiotoxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Asymptomatic, absolute decrease in LVEF &gt;10% (from baseline) and less than the institutional LLN</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for 2 weeks and repeat LVEF. If LVEF ≥ LLN and absolute decrease from baseline is ≤10%, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if LVEF &lt; LLN or absolute decrease from baseline is &gt;10%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic LVEF decrease from baseline</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks and repeat LVEF. If symptoms resolve and LVEF ≥ LLN and absolute decrease from baseline is ≤10%, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if symptoms persist or LVEF &lt; LLN or absolute decrease from baseline is &gt;10%.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">CPK elevation or rhabdomyolysis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 CPK elevation (&gt;10 times ULN) or any CPK elevation with myalgia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks; if improves to grade 3 or lower, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved within 4 weeks.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (intolerable) or grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold or reduce cobimetinib dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">New primary cutaneous or noncutaneous malignancy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No cobimetinib dosage modification is necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Suspicious lesions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manage with excision and dermatopathologic evaluation.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks; if improves to grades 0 or 1, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved within 4 weeks.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cobimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Ocular</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serous retinopathy</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks; if signs/symptoms improve, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved or if symptoms recur within 4 weeks at the lower dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal vein occlusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cobimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Photosensitivity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (intolerable), grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks; if improves to grades 0 or 1, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved within 4 weeks.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Other toxicities</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (intolerable), or any grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib for up to 4 weeks; if improves to grades 0 or 1, resume cobimetinib at the next lower dose level. Permanently discontinue cobimetinib if not improved within 4 weeks.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4, first occurrence</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold cobimetinib until adverse reaction improves to grade 0 or 1 and then resume cobimetinib at the next lower dose level or permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4, recurrent</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue cobimetinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F45655181"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F45642714"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported as part of combination chemotherapy regimens in adults.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased left ventricular ejection fraction (grades 2/3: 26%), hypertension (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption (16%), skin photosensitivity (46%), skin rash (grades 3/4: 2% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (26%), hypoalbuminemia (42%), hypocalcemia (24%), hypokalemia (25%), hyponatremia (38%), hypophosphatemia (68%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (60%; grades 3/4: 6%), nausea (41%; grades 3/4: 1%), stomatitis (14%; grades 3/4: 1%), vomiting (24%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (69%; grades 3/4: 3%), hemorrhage (13%; grades 3/4: 1%), lymphocytopenia (73%; grades 3/4: 10%), thrombocytopenia (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (65%), increased serum alanine aminotransferase (68%), increased serum alkaline phosphatase (71%), increased serum aspartate aminotransferase (73%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (79%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinopathy (serious: 26%; including chorioretinopathy [13%] and retinal detachment [12%]), visual impairment (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (100%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (28%)</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma (5%), squamous cell carcinoma of skin (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genitourinary tract hemorrhage (2%), hematuria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Keratoacanthoma (≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal bilirubin levels (grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant melanoma (second primary), malignant neoplasm (noncutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage</p></div>
<div class="block coi drugH1Div" id="F45624168"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Known hypersensitivity to cobimetinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F45654894"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiomyopathy: Symptomatic or asymptomatic declines in left ventricular ejection fraction (LVEF) may occur with cobimetinib. Safety has not been established in patients with baseline LVEF below the institutional lower limit of normal (LLN) or below 50%. The median time to first onset of LVEF decline was 29 days to 4 months (range: 22 days to 13 months). Decreased LVEF resolved to &gt;LLN or within 10% of baseline at nearly two-thirds of patients with a median time to resolution of ~1 to 3 months (range: 4 days to 12 months).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Severe rash and other skin reactions (including grades 3 and 4 toxicity) may occur; some events required hospitalization. The median time to onset of grade 3 and 4 rash events was 11 days (range: 3 days to ~3 months); most patients with grades 3 and 4 rash experienced complete resolution at a median time of 21 days (range: 4 days to 17 months). Photosensitivity was reported in nearly one-half of patients (may be severe). The median time to first onset of photosensitivity was 2 months (range: 1 day to 14 months); the median duration was 3 months (range: 2 days to 14 months). Photosensitivity resolved in nearly two-thirds of patients. Advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum UVA/UVB sunscreen and lip balm (≥SPF 30) when outdoors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Hemorrhage, including major symptomatic bleeding in a critical area/organ, may occur with cobimetinib. Grade 3 to 4 bleeding has occurred. Cerebral hemorrhage, GI bleeding, reproductive system hemorrhage, and hematuria have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity (including grades 3 or 4 transaminase, total bilirubin, or alkaline phosphatase elevations) may occur with cobimetinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Hypertension has been observed with cobimetinib in combination with vemurafenib, including grades 3 or 4 hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: New primary cutaneous malignancies may occur. Malignancies included cutaneous squamous cell carcinoma (cuSCC) or keratoacanthoma (KA), basal cell carcinoma (BCC), and second primary melanoma. The median time to detection of first cuSCC or KA was 4 months (range: 2 to 11 months); the median time to first detection of BCC was 4 months (range: ~1 to 13 months). The time to onset of second primary melanoma (rare) was 9 to 12 months. Vemurafenib may be associated with the development of noncutaneous malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Ocular toxicities may occur, including serous retinopathy (fluid accumulation under retina layers). Chorioretinopathy and retinal detachment have been reported; retinal vein occlusion has also been reported (case reports). The time to first onset of serous retinopathy ranged between 2 days to 9 months with a duration of 1 day to 15 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Rhabdomyolysis and creatine phosphokinase (CPK) elevations may occur with cobimetinib. The median time to first occurrence of grade 3 or 4 CPK elevations was 16 days (range: 12 days to 11 months), with a median time to resolution of 15 days (range: 9 days to 11 months). If CPK is elevated, evaluate for signs/symptoms of rhabdomyolysis or other etiology.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Prior to initiating therapy when used in combination with vemurafenib in patients with unresectable or metastatic melanoma, confirm BRAF V600K or V600E mutation status with an approved test; approved for use in patients with BRAF V600K and BRAF V600E mutations. Not indicated for use in patients with wild-type BRAF melanoma.</p></div>
<div class="block foc drugH1Div" id="F45691975"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cotellic: 20 mg</p></div>
<div class="block geq drugH1Div" id="F45691973"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46105218"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cotellic Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $150.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872095"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cotellic: 20 mg</p></div>
<div class="block accres drugH1Div" id="F45654891"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty pharmacies. Further information may be obtained from the manufacturer, Genentech, at 1-888-249-4918, or at http://www.cotellic.com.</p></div>
<div class="block adm drugH1Div" id="F45655186"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food. In a clinical trial, cobimetinib tablets were administered whole with water; tablets should not be chewed, cut, or crushed (Larkin 2013 [Protocol GO28141]).</p></div>
<div class="block hazard drugH1Div" id="F49130956"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Cobimetinib may cause teratogenicity, reproductive toxicity, and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F45624167"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Histiocytic neoplasms:</b> Treatment of histiocytic neoplasms in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic:</b> Treatment of unresectable or metastatic melanoma in adults with a BRAF V600E or V600K mutation (in combination with vemurafenib).</p></div>
<div class="block mst drugH1Div" id="F45654889"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cobimetinib may be confused with binimetinib, cabozantinib, capmatinib, ceritinib, crizotinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">Cotellic may be confused with cobicistat.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45654759"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F45654756"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Cobimetinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cobimetinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Cobimetinib. Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cobimetinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Cobimetinib may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F54272451"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase cobimetinib serum concentrations. Management: Avoid grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F49296858"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant should use effective contraception during therapy and for 2 weeks after the final cobimetinib dose.</p></div>
<div class="block pri drugH1Div" id="F45654892"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to cobimetinib would be expected to cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F45654893"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if cobimetinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 2 weeks after the last cobimetinib dose.</p></div>
<div class="block dic drugH1Div" id="F54272452"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice.</p></div>
<div class="block mop drugH1Div" id="F45655188"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">BRAF V600K or V600E mutation status (prior to treatment when used in combination with vemurafenib in unresectable or metastatic melanoma); LFTs (baseline and monthly during treatment, more frequently if clinically indicated); creatine phosphokinase (CPK) and serum creatinine (baseline and periodically during treatment, more frequently if clinically indicated); electrolytes (prior to and routinely during treatment). Assess left ventricular ejection fraction (LVEF) by echocardiogram or multiple-gated acquisition (MUGA) scan prior to therapy initiation, 1 month after initiation, and every 3 months thereafter until cobimetinib is discontinued; also assess LVEF at ~2 weeks, 4 weeks, 10 weeks, 16 weeks, and then as clinically indicated after a dose reduction or treatment interruption. Monitor ECG prior to and routinely during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic exams (baseline, every 2 months during treatment, and for 6 months following discontinuation); ophthalmic examinations (baseline, regularly during treatment and with reports of new or worsening visual disturbances); monitor for signs/symptoms of dermatologic toxicity, hemorrhage, noncutaneous malignancy, photosensitivity, and rhabdomyolysis. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring specifics: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as outpatient monitoring weekly for initial 3 months, then monthly thereafter). In patients receiving cobimetinib plus vemurafenib assess ECG at baseline, at 2 and 4 weeks, then every 3 months thereafter; obtain a baseline echocardiography in high- and very-high risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (consider repeating every 4 months during the first year); consider echocardiography in low- and moderate-risk patients scheduled to receive BRAF-MEK inhibitor combination therapy (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F45654897"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cobimetinib is a potent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway (Larkin 2014); it reversibly inhibits MEK1 and MEK2, which are upstream regulators of the extracellular signal-related kinase (ERK) pathway. The ERK pathway promotes cellular proliferation. MEK1 and MEK2 are part of the BRAF pathway, which is activated by BRAF V600E and K mutations. Vemurafenib targets a different kinase in the RAS/RAF/MEK/ERK pathway; when cobimetinib and vemurafenib are used in combination, increased apoptosis and reduced tumor growth occurs.</p></div>
<div class="block phk drugH1Div" id="F45654899"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 806 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95%; to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; via CYP3A4 oxidation and UGT2B7 glucuronidation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability, absolute: 46%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, mean: 44 hours (range: 23 to 70 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, median: 2.4 hours (range: 1 to 24 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (76%; ~7 as unchanged drug); Urine (~18%; ~2% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 13.8 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51220855"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Exposure was decreased by 31% in patients with severe hepatic impairment compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45650002"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cotellic</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cobimetinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cotellic.1">
<a name="Cotellic.1"></a>Cotellic (cobimetinib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cotellic.2">
<a name="Cotellic.2"></a>Cotellic (cobimetinib) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32534646">
<a name="32534646"></a>Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2020;395(10240):1835-1844. doi:10.1016/S0140-6736(20)30934-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cobimetinib-drug-information/abstract-text/32534646/pubmed" id="32534646" target="_blank">32534646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cobimetinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25265494">
<a name="25265494"></a>Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>N Engl J Med</i>. 2014;371(20):1867-1876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cobimetinib-drug-information/abstract-text/25265494/pubmed" id="25265494" target="_blank">25265494</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Larkin J, Ascierto PA, Dréno B, et al; for F. Hoffmann-La Roche Ltd. Protocol GO28141, Version 4: a phase III, double-blind, placebo-controlled study of vemurafenib versus vemurafenib plus GDC-0973 in previously untreated BRAF<sup>V600</sup>-mutation positive patients with unresectable locally advanced or metastatic melanoma. Updated September 12, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cobimetinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 105354 Version 139.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
